ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Tafluprost: Drug information

Tafluprost: Drug information
(For additional information see "Tafluprost: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Zioptan
Pharmacologic Category
  • Ophthalmic Agent, Antiglaucoma;
  • Prostaglandin, Ophthalmic
Dosing: Adult
Elevated intraocular pressure

Elevated intraocular pressure: Ophthalmic: One drop in the affected eye(s) once daily in the evening; do not exceed the once daily dosage because it has been shown that more frequent administration may decrease the IOP-lowering effect.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Older Adult

Refer to adult dosing.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%: Ophthalmic: Conjunctival hyperemia (4% to 20%)

1% to 10%:

Central nervous system: Headache (6%)

Genitourinary: Urinary tract infection (2%)

Infection: Common cold (4%)

Ophthalmic: Eye irritation (≤7%), stinging of eyes (≤7%), conjunctivitis (5%), cataract (3%), eye pain (3%), xerophthalmia (3%), blurred vision (2%), hyperpigmentation of eyelashes (2%), increased eyelash length (2%)

Respiratory: Cough (3%)

<1%, postmarketing, and/or case reports: Dyspnea, exacerbation of asthma, iris hyperpigmentation, iritis, uveitis

Contraindications

There are no contraindications listed in the manufacturer’s prescribing information.

Warnings/Precautions

Concerns related to adverse effects:

• Ocular effects: May change/increase brown pigmentation of the iris, eyelid, and eyelashes; length, color, thickness, shape, and/or number of eyelashes may also be increased. Pigmentation of the iris is likely to be permanent although iris color change may not be noticeable for months to years; pigmentation of the eyelid and eyelash changes may be reversible following discontinuation of therapy. Long-term consequences and potential injury to eye are not known.

Disease-related concerns:

• Ocular disease: Use with caution in patients with intraocular inflammation, aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with risk factors for macular edema.

Special populations:

• Pediatric: Use in pediatric patients is not recommended due to possible safety issues of increased pigmentation following long-term use.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Ophthalmic [preservative free]:

Zioptan: 0.0015% (10 ea) [contains disodium edta, polysorbate 80]

Generic: 0.0015% (5 ea, 10 ea)

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Tafluprost (PF) Ophthalmic)

0.0015% (per each): $8.10 - $8.74

Solution (Zioptan Ophthalmic)

0.0015% (per each): $9.20

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Adult

For ophthalmic use only. Wash hands before use. Avoid touching the tip of the single-use container to eye or other surfaces. Each single-use container has adequate solution to treat both eyes (if applicable); discard immediately after use. If more than one topical ophthalmic drug is being used, administer the drugs at least 5 minutes apart.

Use: Labeled Indications

Elevated intraocular pressure: Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Latanoprost: The concomitant use of Prostaglandins (Ophthalmic) and Latanoprost may result in increased intraocular pressure. Risk X: Avoid combination

Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). Risk C: Monitor therapy

Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents (Ophthalmic) may enhance the therapeutic effect of Prostaglandins (Ophthalmic). Risk C: Monitor therapy

Reproductive Considerations

Ophthalmic prostaglandins, such as tafluprost, have a theoretical risk of miscarriage. To decrease this risk, agents other than tafluprost may be preferred for the treatment of glaucoma in patients planning to become pregnant (Strelow 2020). The manufacturer recommends patients of childbearing potential use effective contraception during treatment with tafluprost

Pregnancy Considerations

Ophthalmic prostaglandins, such as tafluprost, are generally avoided during pregnancy due to a theoretical risk of miscarriage and premature labor. Agents other than tafluprost may be preferred for the treatment of glaucoma during pregnancy, especially during the first trimester. In general, if ophthalmic agents are needed in pregnancy, the minimum effective dose should be used in combination with punctal occlusion to decrease exposure to the fetus (Belkin 2020; Prum 2016; Strelow 2020).

Breastfeeding Considerations

It is not known if tafluprost is present in breast milk.

The manufacturer recommends that caution be exercised when administering tafluprost to breastfeeding patients. Due to their short half-lives, ophthalmic prostaglandins, such as tafluprost, are considered compatible with breastfeeding; administering after breastfeeding may help decrease potential exposure to the infant via breast milk (Belkin 2020; Prum 2016; Strelow 2020).

Monitoring Parameters

Intraocular pressure; regularly examine patients who develop increased iris pigmentation

Mechanism of Action

Tafluprost acid is a fluorinated prostaglandin F2-alpha analog believed to reduce intraocular pressure by increasing outflow of aqueous humor via the uveoscleral pathway; exact mechanism by which it reduces IOP is unknown.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Reduction of intraocular pressure (IOP): 2 to 4 hours

Peak effect: Maximum reduction of IOP: ~12 hours

Absorption: Through the cornea

Metabolism: Ester prodrug (tafluprost) is hydrolyzed to the biologically active acid metabolite (tafluprost acid); tafluprost acid metabolized further via fatty acid beta oxidation and phase II conjugation

Time to peak, plasma: ~10 minutes

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Saflutan;
  • (AR) Argentina: Saflutan;
  • (AT) Austria: Saflutan;
  • (AU) Australia: Saflutan;
  • (BD) Bangladesh: Taflan;
  • (BE) Belgium: Saflutan;
  • (BG) Bulgaria: Taflotan;
  • (BR) Brazil: Saflutan;
  • (CH) Switzerland: Saflutan;
  • (CL) Chile: Saflutan;
  • (CN) China: Tapros;
  • (CO) Colombia: Saflutan;
  • (CZ) Czech Republic: Taflotan;
  • (DE) Germany: Taflotan | Taflotan sine;
  • (DO) Dominican Republic: Saflutan;
  • (EE) Estonia: Taflotan;
  • (EG) Egypt: Saflutan;
  • (ES) Spain: Saflutan;
  • (FI) Finland: Taflotan;
  • (FR) France: Saflutan;
  • (GB) United Kingdom: Saflutan;
  • (GR) Greece: Saflutan;
  • (HK) Hong Kong: Taflotan;
  • (HR) Croatia: Saflutan;
  • (HU) Hungary: Taflotan;
  • (ID) Indonesia: Taflotan;
  • (IE) Ireland: Saflutan;
  • (IN) India: Saflutan;
  • (IT) Italy: Safluround | Saflutan;
  • (JO) Jordan: Saflutan | Taflupro;
  • (JP) Japan: Tapros;
  • (KR) Korea, Republic of: Taflotan | Taflotan s;
  • (KW) Kuwait: Saflutan;
  • (LB) Lebanon: Saflutan;
  • (LT) Lithuania: Taflotan;
  • (LU) Luxembourg: Saflutan;
  • (LV) Latvia: Taflotan | Taflotan sine;
  • (MA) Morocco: Zioptan;
  • (MX) Mexico: Saflutan;
  • (MY) Malaysia: Taflotan | Taflotan s;
  • (NL) Netherlands: Saflutan | Tafluprost fisher;
  • (NO) Norway: Taflotan;
  • (PE) Peru: Saflutan;
  • (PH) Philippines: Taflotan;
  • (PL) Poland: Taflotan | Taflotan multi;
  • (PR) Puerto Rico: Zioptan;
  • (PT) Portugal: Saflutan | Taflotan;
  • (QA) Qatar: Saflutan;
  • (RU) Russian Federation: Taflopress rompharm | Taflotan;
  • (SE) Sweden: Saflutan | Taflotan;
  • (SG) Singapore: Taflotan | Taflotan s;
  • (SI) Slovenia: Saflutan;
  • (SK) Slovakia: Taflotan;
  • (TH) Thailand: Taflotan | Taflotan s;
  • (TR) Turkey: Saflutan;
  • (TW) Taiwan: Taflotan | Taflotan s;
  • (UA) Ukraine: Taflotan multi;
  • (ZA) South Africa: Saflutan
  1. Belkin A, Chen T, DeOliveria AR, Johnson SM, Ramulu PY, Buys YM; American Glaucoma Society and the Canadian Glaucoma Society. A practical guide to the pregnant and breastfeeding patient with glaucoma. Ophthalmol Glaucoma. 2020;3(2):79-89. doi:10.1016/j.ogla.2019.12.004 [PubMed 32672600]
  2. Prum BE Jr, Rosenberg LF, Gedde SJ, et al. Primary open-angle glaucoma preferred practice pattern guidelines. Ophthalmology. 2016;123(1):P41-P111. doi:10.1016/j.ophtha.2015.10.053 [PubMed 26581556]
  3. Strelow B, Fleischman D. Glaucoma in pregnancy: an update. Curr Opin Ophthalmol. 2020;31(2):114-122. doi:10.1097/ICU.0000000000000641 [PubMed 31922978]
  4. Zioptan (tafluprost) [prescribing information]. Lake Forest, IL: Akorn Inc; May 2022.
Topic 83329 Version 146.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟